Kadijeh Tati1, Mahsa Yazdanpanah-Samani2, Amin Ramezani3, Elham Mahmoudi Maymand2, Abbas Ghaderi2. 1. Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical sciences, Shiraz, Iran; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical sciences, Shiraz, Iran. 3. Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical sciences, Shiraz, Iran; Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
BACKGROUND: CD52 is a small glycoprotein with a GPI anchor at its C-terminus. CD52 is expressed by Normal and malignant T and B lymphocytes and monocytes. There are detectable amounts of soluble CD52 in plasma of patients with CLL and could be used as a tumor marker. Although the biological function of CD52 is unknown but it seems that CD52 may be involved in migration and activation of T-cells .The aim of this study was to clone and express human CD52 gene in CHO cell line and studying its function in more details. METHODS: Based on GenBank databases two specific primers were designed for amplification of cd52 gene. Total RNA was extracted from Raji cell line and cDNA synthesized. Amplified fragment was cloned in pBudCE4.1 vector. The new construct was transfected to CHO-K1 cell line using electroporation method. Expression of recombinant CD52 protein was evaluated by Real time PCR and flow cytometry methods. RESULTS: Amplification of CD52 gene using specific primers on Raji cDNA showed a 209 bp band. New construct was confirmed by PCR and restriction pattern and sequence analysis. The new construct was designated as pBudKT1. RT-PCR analysis detected cd52 mRNAs in transfected cells and Flow cytometry Results showed that 78.4 % of cells represented CD52 in their surfaces. CONCLUSION: In conclusion, we established a human CD52 positive cell line, CHO-CD52, and the protein was expressed on the membrane. Cloning of the CD52 gene could be the first step for the production of therapeutic monoclonal antibodies and detection systems for soluble CD52 in biological fluids.
BACKGROUND:CD52 is a small glycoprotein with a GPI anchor at its C-terminus. CD52 is expressed by Normal and malignant T and B lymphocytes and monocytes. There are detectable amounts of soluble CD52 in plasma of patients with CLL and could be used as a tumor marker. Although the biological function of CD52 is unknown but it seems that CD52 may be involved in migration and activation of T-cells .The aim of this study was to clone and express humanCD52 gene in CHO cell line and studying its function in more details. METHODS: Based on GenBank databases two specific primers were designed for amplification of cd52 gene. Total RNA was extracted from Raji cell line and cDNA synthesized. Amplified fragment was cloned in pBudCE4.1 vector. The new construct was transfected to CHO-K1 cell line using electroporation method. Expression of recombinant CD52 protein was evaluated by Real time PCR and flow cytometry methods. RESULTS: Amplification of CD52 gene using specific primers on Raji cDNA showed a 209 bp band. New construct was confirmed by PCR and restriction pattern and sequence analysis. The new construct was designated as pBudKT1. RT-PCR analysis detected cd52 mRNAs in transfected cells and Flow cytometry Results showed that 78.4 % of cells represented CD52 in their surfaces. CONCLUSION: In conclusion, we established a humanCD52 positive cell line, CHO-CD52, and the protein was expressed on the membrane. Cloning of the CD52 gene could be the first step for the production of therapeutic monoclonal antibodies and detection systems for soluble CD52 in biological fluids.
Entities:
Keywords:
CD52; Recombinant DNA; Therapeutic and diagnostic proteins
Authors: Gregor Hoermann; Katharina Blatt; Georg Greiner; Eva Maria Putz; Angelika Berger; Harald Herrmann; Sabine Cerny-Reiterer; Karoline V Gleixner; Christoph Walz; Konrad Hoetzenecker; Leonhard Müllauer; Andreas Reiter; Karl Sotlar; Veronika Sexl; Peter Valent; Matthias Mayerhofer Journal: FASEB J Date: 2014-04-23 Impact factor: 5.191
Authors: Maher Albitar; Kim-Anh Do; Marcella M Johnson; Francis J Giles; Iman Jilani; Susan O'Brien; Jorge Cortes; Deborah Thomas; Laura Z Rassenti; Thomas J Kipps; Hagop M Kantarjian; Michael Keating Journal: Cancer Date: 2004-09-01 Impact factor: 6.860
Authors: Yanping Hu; Michael J Turner; Jacqueline Shields; Matthew S Gale; Elizabeth Hutto; Bruce L Roberts; William M Siders; Johanne M Kaplan Journal: Immunology Date: 2009-10 Impact factor: 7.397
Authors: Liaqat Ali; Gauri Saxena; Meleri Jones; Georgia R Leisegang; Luke Gammon; Sharmilee Gnanapavan; Gavin Giovannoni; Klaus Schmierer; David Baker; Angray S Kang Journal: Biotechniques Date: 2020-02-25 Impact factor: 1.993